GRAL - NASDAQ

GRAIL, Inc.

GRAL·NASDAQ

$61.13

-5.1%

HealthcareMedical - Diagnostics & Research

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.62B

EPS-11.1100

P/E Ratio-5.50

Earnings Date08/11/2026

gral

Net Cash Provided by Financing Activities

Last Annual Value

423.32M

3-Year CAGR

-11%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

GRAIL, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

GRAL · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
GRAIL, Inc. NASDAQ:GRAL	423.32M	-3.0%	1.4%	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	137.16M	-8.7%	N/A	29.0%
Celcuity Inc. NASDAQ:CELC	360.55M	77.1%	31.1%	58.0%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	478.00M	7.2%	32.2%	13.2%
Envista Holdings Corp NYSE:NVST	-170.90M	N/A	N/A	N/A
Apogee Therapeutics, Inc. NASDAQ:APGE	396.49M	7.9%	N/A	N/A
IDEAYA Biosciences, Inc. NASDAQ:IDYA	29.78M	-56.5%	-27.2%	N/A
Dyne Therapeutics, Inc. NASDAQ:DYN	890.31M	154.0%	41.3%	-10.6%

GRAIL, Inc. Fair Value Envelope

GRAL · NASDAQ

Our analysis suggests that GRAL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $61.13, this represents a potential HIDDEN relative to our calculated worth for GRAIL, Inc..

HIDDEN

Intrinsic Value

Current Price: $61.13

Related Guides

Blog Categories

Continue your GRAL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.